UNSPSC 51102847: Fluocinolone/neomycin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102847 Fluocinolone/neomycin is a Commodity code that nominally names a specific topical antibiotic-corticosteroid combination, but recent state and local procurement activity under this code shows substantial mismatch with that scope. The source records pharmaceutical and medical supply procurements that diverge sharply from the code's name: Seminole County, Florida has solicited naloxone and drug deactivation systems; the City of Tampa has requested medical and first aid supplies for fire rescue operations; the Texas Health and Human Services Commission has issued an RFI on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has sought generic multi-source pharmaceuticals and OTC products through wholesalers. None of these opportunities involve fluocinolone/neomycin topical preparations. The code shows little relevant recent activity aligned to its nominal product scope, and appears to be a classification mismatch in the state and local procurement systems from which these records were drawn.

The geographic spread of the four opportunities identified spans Florida, Texas, Minnesota, and Oregon (as a MMCAP participating state), but the heterogeneous nature of the solicitations—ranging from a local fire department's emergency medical supplies to a multi-state cooperative's pharmaceutical wholesaler network—reflects fragmentation rather than a coherent procurement pattern under this code. Response dates and issuing bodies are documented (Seminole County IFB due July 26, 2023; Tampa Fire Department IFB due March 13, 2026 with $700,000 estimated value; MMCAP RFP due March 26, 2026; Texas HHS RFI due April 3, 2026), but the absence of substantive fluocinolone/neomycin activity suggests this Commodity code is not a reliable signal for business development targeting under its stated scope.